Skip to content

Heart Transplant

  • Heart Transplant Home
  • AlloMap
  • HeartCare

AlloMap Heart is a non-invasive gene expression profile test for heart allograft surveillance. AlloMap Heart is an established standard for heart transplant surveillance. Recommended in ISHLT guidelines and used in over 90% of transplant centers.

HeartCare combines both AlloMap Heart (gene expression profiling) and AlloSure Heart (dd-cfDNA). HeartCare provides meaningful information about recipient immune activity and donor graft injury. HeartCare is now available through the SHORE study.

Request Information

Subscribe

* indicates required
I am a

GENE EXPRESSION PROFILING

THE STANDARD OF CARE FOR Non-Invasive MANAGEMENT OF HEART TRAnSPLANT RECIPIENTS.

AlloMap Heart is a non-invasive gene expression profile test of peripheral blood in heart transplant recipients. AlloMap Heart is used by over 90% of US transplant centers. AlloMap Heart is covered by Medicare and most private health plans.

What is AlloMap?

AlloMap Heart is panel of 11 informative genes and 9 controlled genes. AlloMap Heart detects changes in gene expression associated with acute rejection and provides an actionable score.

What is a GENE EXPRESSION PROFILING?

AlloMap Heart detects changes in gene expression of peripheral blood cells for 11 genes involved in the immune response. These genes were selected and validated for their association with acute cellular rejection in heart transplant patients.

USED IN OVER 90% OF TRANSPLANT CLINICS

Since its introduction in 2005, AlloMap has helped to:

  • Give providers information on the risk of acute cellular rejection in their patients following heart transplant

FDA cleared

The FDA’s AlloMap Decision Summary is available here.

Request Information

Subscribe

* indicates required
I am a

Comprehensive Insights

THE NEW SURVEILLANCE SOLUTION. ONE BLOOD DRAW, TWO PERSPECTIVES.

HeartCare provides meaningful information about recipient immune activity and donor graft injury. Encompassing both AlloMap Heart® (immune activity mRNA) and AlloSure Heart® (graft injury cfDNA), HeartCare provides a more comprehensive assessment of graft rejection.

What is HeartCare?

HeartCare provides a new dimension of information to manage heart transplant recipients by combining the industry standard AlloMap Heart (gene expression profiling) test and AlloSure Heart (donor-derived cell-free DNA) to provide valuable information about distinct biological processes.

IMMUNE ACTIVITY

AlloMap Heart detects changes in gene expression of peripheral blood cells for 11 genes involved in the immune response. These genes were selected and validated for their association with acute cellular rejection in heart transplant patients.

GRAFT INJURY

AlloSure Heart detects injury and rejection by measuring the amount of donor cell-free DNA in the blood. Cell-free DNA is DNA in the blood that originates from cells undergoing cell injury and death. AlloSure Heart is a powerful surveillance tool for measuring organ rejection and was clinically validated in three independent, prospective studies.

Request Information

Subscribe

* indicates required
I am a